BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bex A, Haanen J. Do targeted agents offer clinical benefit as presurgical therapy? World J Urol 2014;32:3-8. [DOI: 10.1007/s00345-013-1041-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Puente Vázquez J, Alonso Gordoa T, Moreno J, Poma L, Diaz Rubio E, Gomez A, Blazquez J, Gonzalez Larriba JL. New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies. Curr Treat Options in Oncol 2015;16. [DOI: 10.1007/s11864-015-0337-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Krabbe LM, Haddad AQ, Westerman ME, Margulis V. Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol 2014;32:615-22. [PMID: 24700309 DOI: 10.1007/s00345-014-1286-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med 2014;6:1561-76. [PMID: 25361689 DOI: 10.15252/emmm.201403989] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
4 Poprach A, Holanek M, Chloupkova R, Lakomy R, Stanik M, Fiala O, Melichar B, Kopeckova K, Zemanova M, Kiss I, Penka I, Bohosova J, Buchler T. Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry. Cancers (Basel) 2020;12:E2911. [PMID: 33050532 DOI: 10.3390/cancers12102911] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lane BR, Derweesh IH, Kim HL, O'Malley R, Klink J, Ercole CE, Palazzi KL, Thomas AA, Rini BI, Campbell SC. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol 2015;33:112.e15-21. [PMID: 25532471 DOI: 10.1016/j.urolonc.2014.11.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
6 Jackson BL, Fowler S, Williams ST; the British Association of Urological Surgeons (BAUS) - Section of Oncology. Perioperative outcomes of cytoreductive nephrectomy in the UK in 2012. BJU Int 2015;116:905-10. [DOI: 10.1111/bju.12890] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
7 Grivas NK. Neoadjuvant targeted therapy for advanced renal cell carcinoma: Where do we stand? Urol Ann 2019;11:115-6. [PMID: 30787586 DOI: 10.4103/0974-7796.250549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]